Alembic Pharmaceuticals Limited (APLLTD) — Announcement

1 Announcement Neutral 📄 PDF

📢 Key Event
Alembic receives USFDA tentative approval for Binimetinib 45 mg tablets

💡 Investor Takeaway
Investors should note this approval could unlock future revenue from a high-value oncology indication.

Alembic Pharmaceuticals announced that its USFDA tentative approval for Binimetinib 45 mg tablets has been granted, marking the first Paragraph IV filing for this indication and positioning the company to potentially capture a $259 million market opportunity in melanoma and NSCLC treatments.

2 Announcement Neutral 📄 PDF

📢 Key Event
Alembic schedules investor one-on-one meetings

💡 Investor Takeaway
Retail investors can engage directly with management during these meetings.

Alembic Pharmaceuticals announced scheduled one-on-one investor meetings on June 22, 23, and 25, 2026, with HDFC Mutual Fund, Tata Mutual Fund, and HDFC Life Insurance, conducted in Mumbai and via video conference. These meetings provide retail investors direct access to management without publishing price-sensitive information.

📊 Stock Analysis — APLLTD ✨ Ask AI About This